Fatal-Plus 390 mg Solution is a Health Canada–registered veterinary drug (DIN 02522098) held by Grey Wolf Animal Health Inc, containing Pentobarbital Sodium. Health Canada lists its status as Marketed (status date 06 May 2025). Nexara Health has matched 31 registrations of Pentobarbital Sodium across 5 other regulated markets.

Health Canada registration

Pentobarbital Sodium registered in other markets

31 registrations of the same molecule in 5 national registries outside Canada (first 28 shown, exact strength and form first). Each row is taken from the regulator's own published list; status is shown as the registry reports it.

See every manufacturer of Pentobarbital Sodium worldwide →

Regulator price references for Pentobarbital Sodium

Published list or reimbursement prices for Pentobarbital Sodium presentations, in local currency, as at the date each registry last published. These are public reference prices, not Nexara Health quotes; strength and pack differ by row.

Sourcing through Nexara Health

Nexara Health is a Health Canada–licensed wholesaler (DEL #3-002896) in Winnipeg. Because this DIN is marketed in Canada, supply normally comes through the Canadian channel; where the Canadian presentation is short or discontinued, the registrations above show which regulated markets hold an equivalent that can be imported under the Special Access Programme or for clinical comparator use. Request a quote or read how named-patient and foreign-pack supply works in Canada.

Frequently asked questions

Is Fatal-Plus (DIN 02522098) marketed in Canada?

Yes. Health Canada lists DIN 02522098 as Marketed as of 06 May 2025.

Who holds the Canadian licence for this product?

Grey Wolf Animal Health Inc is the company of record in the Health Canada Drug Product Database.

Is Pentobarbital Sodium registered outside Canada?

Yes — Nexara Health has matched 31 registrations in 5 other markets (see the table above).

Where does this data come from?

Health Canada Drug Product Database (DPD), DIN 02522098, status date 2025-05-06; national medicine registries: DH Drug Office, FDA NDC, Fimea Perusrekisteri, Lyfjastofnun lyfjaverdskra, TFDA; price sources: Lyfjastofnun lyfjaverdskra. Nexara Health re-checks these sources weekly and shows the last verification date at the top of the page.

Source: Health Canada Drug Product Database (DPD), DIN 02522098, status date 2025-05-06; national medicine registries: DH Drug Office, FDA NDC, Fimea Perusrekisteri, Lyfjastofnun lyfjaverdskra, TFDA; price sources: Lyfjastofnun lyfjaverdskra.

Health Canada Drug Product Database (DPD), DIN 02522098, status date 2025-05-06; national medicine registries: DH Drug Office, FDA NDC, Fimea Perusrekisteri, Lyfjastofnun lyfjaverdskra, TFDA; price sources: Lyfjastofnun lyfjaverdskra. Last reviewed 2026-09-16. Nexara Health is a licensed wholesaler and supplies licensed entities only; consumer orders are routed to a partner pharmacy.